Biologicals represent the future of pharmaceutical treatments and innovation. Yet, emerging and developing markets lack access to these often essential medicines. Biosimilar development represents a potential solution to this problem, by off ering lower cost and improved access, but is also associated with patient safety issues. In order to synergize these divergent challenges, targeted public−private partnerships that bring together shared goals and resources of the public sector, global fi

more »

... , and local manufacturers need to be explored. Crucial to their success will be equitable intellectual property rights management and coordination and collaboration with eff ective governance and incentives.